Robin Shane Readnour, Director at AN2 Therapeutics, Inc. (ANTX), bought 37,500 shares at $1.42 ($53K) on 2024-11-27, disclosed to the SEC on 2024-11-27.
Open-market purchase of $53k ANTX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.39 | 12,500 | $17K | 32.9% |
| 2 | $1.42 | 25,000 | $36K | 67.1% |
| Total | $1.41 avg | 37,500 | $53K | 100% |
| Filing → |
| ANTX | SELL | 2026-08-19 | $213K | — | Filing → |
| ANTX | BUY | 2024-12-10 | $79K | — | Filing → |
| ANTX | BUY | 2024-11-21 | $213K | — | Filing → |